Arca
Skip to content
Tools
Tools

Warning Letter to Aurobindo Pharma Limited

Drugs. See Aurobindo Pharma's company page or this site's inspections.

On Feb 9, 2023, FDA's CDER sent Aurobindo Pharma Limited a warning letter.

  • Letter date: Feb 9, 2023
  • Issued by: CDER
  • Closeout: โ€”

The Letter

As posted on FDA.gov โ†—; cited 21 CFR sections link to their page.

Dear Mr. Reddy:

The Food and Drug Administration (FDA) has completed an evaluation of your firmโ€™s corrective actions in response to our Warning Letter 320-19-27 dated June 20, 2019.

Based on our evaluation, it appears that you have addressed the deviations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.

This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority.

The FDA expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter will not preclude any future regulatory action deviations be observed during a subsequent inspection or through other means.

Sincerely, /S/ Tamara Rosbury, Ph.D. Compliance Officer Division of Drug Quality II

The Firm's Other Letters

Same company or the same FDA site, newest first

Record

Recipient
Mr. K. Nithyananda Reddy
FDA site ID (FEI)
3004611182
Cited
โ€”

Tags are assigned by Arca from the letter's text. A closeout letter means FDA found the firm's corrections adequate; no closeout does not mean the issues are unresolved. FDA warning letters

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.